Interleukin 8 receptor antagonists - Pipeline Insight, 2022
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “Interleukin 8 receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 6+ pipeline drugs in Interleukin 8 receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Interleukin 8 receptor antagonists: Overview
Interleukin-8 (CXCL8) was the first member to be identified of this new family of proinflammatory chemokines that now constitute over 45 members. Chemokines produce their biological effects by interacting with greater than 18 G protein coupled cell surface receptors. A few chemokines bind selectively to a single receptor but other chemokines bind to more than one receptor. CXCL8 belongs to a subgroup of chemokines known as ELR+ chemokines because of the Glu4-Leu5-Arg6 amino acid sequence between positions 4 and 6. Interleukin-8 is a key mediator associated with inflammation where it plays a key role in neutrophil recruitment and neutrophil degranulation. Interleukin-8 secretion is increased by oxidant stress, which thereby cause the recruitment of inflammatory cells and induces a further increase in oxidant stress mediators, making it a key parameter in localized inflammation. IL-8 was shown to be associated with obesity.
Report Highlights
This segment of the Interleukin 8 receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interleukin 8 receptor antagonists Emerging Drugs
Further product details are provided in the report……..
Interleukin 8 receptor antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Interleukin 8 receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:
Interleukin 8 receptor antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Interleukin 8 receptor antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin 8 receptor antagonists drugs.
Interleukin 8 receptor antagonists Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Interleukin 8 receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 6+ pipeline drugs in Interleukin 8 receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Interleukin 8 receptor antagonists: Overview
Interleukin-8 (CXCL8) was the first member to be identified of this new family of proinflammatory chemokines that now constitute over 45 members. Chemokines produce their biological effects by interacting with greater than 18 G protein coupled cell surface receptors. A few chemokines bind selectively to a single receptor but other chemokines bind to more than one receptor. CXCL8 belongs to a subgroup of chemokines known as ELR+ chemokines because of the Glu4-Leu5-Arg6 amino acid sequence between positions 4 and 6. Interleukin-8 is a key mediator associated with inflammation where it plays a key role in neutrophil recruitment and neutrophil degranulation. Interleukin-8 secretion is increased by oxidant stress, which thereby cause the recruitment of inflammatory cells and induces a further increase in oxidant stress mediators, making it a key parameter in localized inflammation. IL-8 was shown to be associated with obesity.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Interleukin 8 receptor antagonists R&D. The therapies under development are focused on novel approaches for Interleukin 8 receptor antagonists.
This segment of the Interleukin 8 receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interleukin 8 receptor antagonists Emerging Drugs
- Ladarixin: Dompe Farmaceutici
- AZD 5069: AstraZeneca
Further product details are provided in the report……..
Interleukin 8 receptor antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Interleukin 8 receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Interleukin 8 receptor antagonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Interleukin 8 receptor antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Interleukin 8 receptor antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin 8 receptor antagonists drugs.
Interleukin 8 receptor antagonists Report Insights
- Interleukin 8 receptor antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Interleukin 8 receptor antagonists drugs?
- How many Interleukin 8 receptor antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Interleukin 8 receptor antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interleukin 8 receptor antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Interleukin 8 receptor antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Dompe Farmaceutici
- AstraZeneca
- Syntrix Biosystems
- Ligand Pharmaceuticals
- Aristea Therapeutics
- Corvus Pharmaceuticals
- Ladarixin
- AZD 5069
- SX 682
- Reparixin
- Navarixin
- RIST 4721
- CPI 182
Introduction
Executive Summary
Interleukin 8 receptor antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Interleukin 8 receptor antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Ladarixin: Dompe Farmaceutici
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
AZD 5069: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
SX 682: Syntrix Biosystems
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
CPI 182: Corvus Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Interleukin 8 receptor antagonists Key Companies
Interleukin 8 receptor antagonists Key Products
Interleukin 8 receptor antagonists- Unmet Needs
Interleukin 8 receptor antagonists- Market Drivers and Barriers
Interleukin 8 receptor antagonists- Future Perspectives and Conclusion
Interleukin 8 receptor antagonists Analyst Views
Interleukin 8 receptor antagonists Key Companies
Appendix
Executive Summary
Interleukin 8 receptor antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Interleukin 8 receptor antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Ladarixin: Dompe Farmaceutici
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
AZD 5069: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
SX 682: Syntrix Biosystems
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
CPI 182: Corvus Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Interleukin 8 receptor antagonists Key Companies
Interleukin 8 receptor antagonists Key Products
Interleukin 8 receptor antagonists- Unmet Needs
Interleukin 8 receptor antagonists- Market Drivers and Barriers
Interleukin 8 receptor antagonists- Future Perspectives and Conclusion
Interleukin 8 receptor antagonists Analyst Views
Interleukin 8 receptor antagonists Key Companies
Appendix